The Gradinaru Lab has developed an AAV capable of systemic transfection. Recently, the first AAV for widespread systemic use was AAV-PHP.B and published in Nature. Newer variants have also been validated and shared in a Nature Protocols article that includes protocols for production, purification, and administration. AAV-PHP and its variants can be accessed at the Clover Center at Caltech. Since the Clover Center has limited supplies, future plans include disseminating via the Michigan Vector Core.